Public dataset
Recorded source agreement and disagreement
Show whether sources print one normalized reading, have incompatible units, lack structured comparison context, or contain a context-matched numeric difference.
- Public rows
- 1,681
- Generated
- Schema version
- source-consensus/2
Coverage
What this run contains
- Compared medicine fields
- 1,681
- Agree
- 1,282
- Differ
- 0
- Not comparable
- 12
- Insufficient context
- 387
- Fields represented
- 5
- bioavailability, halfLife, proteinBinding, tMax, volumeOfDistribution
Method
How the rows were made
- Deterministic rules normalize recorded pharmacokinetic readings and compare only like-for-like values.
- One normalized printed reading may be agree even when clinical context was not extracted; this reports printed-reading agreement only.
- Distinct readings may differ only when their units and denominators are comparable and one matching, non-placeholder population/formulation context was structurally extracted. Otherwise they are insufficient_context.
- not_comparable preserves incompatible units or denominators instead of guessing. insufficient_context preserves missing or non-matching structured context instead of manufacturing agreement or disagreement.
- The agreement rate describes the distribution of recorded source readings; it is not a probability that a value is true.
- Every distinct printed reading retains its unit, population context, source count, and complete source records. The API paginates field rows, never child readings or sources.
- documentsExamined is every matching single-substance archive document inspected for that medicine. The generator has no document, reading, or source ceiling, so there is no hidden available-versus-retained remainder.
Limits
Read these before using a row
- Current label parsing does not structurally extract population or formulation context. Distinct otherwise-comparable readings are therefore insufficient_context, never differ; agree may mean printed-reading agreement only. Source records are complete but are not independent-experiment counts.
- The current deterministic parser does not structurally extract population or formulation context from these sentences. It records that context as unknown and cannot publish distinct same-unit readings as differ.
- Neither reading is marked wrong. Population, formulation, route, and other unextracted context may explain the printed difference.
- Only the recorded fields and source documents in this snapshot are compared.
- A source count is the number of retained source records in the row, not a count of independent experiments.
Provenance
Source examples
abacavir · bioavailability · agree
15 documents examined; 83% (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:5676d391-f9a4-44be-9604-954b3d8d0e2b (opens source in a new tab)The geometric mean absolute bioavailability of the tablet was 83%.
alemtuzumab · volumeOfDistribution · not_comparable
2 documents examined; 0.18 L/kg (Unknown: population and formulation context were not structurally extracted from this source sentence.); 14.1 L (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:4f5f7255-7abc-4328-bd1a-ceaf139ef3e0 (opens source in a new tab)Distribution After the last 30 mg dose, the mean volume of distribution at steady-state was 0.18 L/kg (range 0.1 to 0.4 L/kg).
abiraterone · halfLife · insufficient_context
31 documents examined; 12 ± 5 hours (Unknown: population and formulation context were not structurally extracted from this source sentence.); 18 hours (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:c9eb9b46-f847-40a8-802c-a51b40406d5a (opens source in a new tab)Elimination In patients with metastatic CRPC, the mean terminal half-life of abiraterone in plasma (mean ± SD) is 12 ± 5 hours.
Artifact used for this view: data/source-consensus.ndjson. The reader resolves the current run first and uses the checked-in compatibility run only when a current artifact is absent.
Schema
Fields in the public projection
| Field | Type | Meaning |
|---|---|---|
| medicineSlug | string | Stable RNAWiki medicine route key. |
| field | string | Recorded pharmacokinetic field being compared. |
| comparisonState | string | agree (printed-reading agreement), differ (context-matched comparable disjoint values), not_comparable (unit/denominator mismatch), or insufficient_context. Every state remains declared even when its current count is zero. |
| comparisonReasons | string[] | Deterministic codes explaining the state. |
| documentsExamined | number | Recorded source documents considered for the field. |
| sourceCount | number | Recorded source readings represented. |
| agreementRate | number | Share represented by the leading normalized printed-reading group; not a confidence score or clinical agreement probability. |
| readings | consensus-reading[] | Complete, untruncated reading groups. Each keeps the printed display, numeric value when parsed, unit, population context, source count, and every source identity, version/effective date or explicit absence, retrieval date, locator, safe link, and excerpt. |
Reader
Search and filter the rows
Showing 271–280 of 1,681 matching rows. Filters and search terms remain attached when you move between pages or open the API view.
Projected row 271
- Medicine slug
- cefotaxime
- Compared field
- halfLife
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 2
- Source count
- 2
- Agreement rate
- 1
- Recorded readings
1 hour
- Numeric value
- 1
- Unit
- hours
- Source records
- 2
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 2 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ed23b6bc-32c7-4c50-a53d-313ae78e5623 (opens source in a new tab)
Cefotaxime label
Version not recorded · Effective date not recorded
CLINICAL PHARMACOLOGY Following IM administration of a single 500 mg or 1 g dose of cefotaxime to normal volunteers, mean peak serum concentrations of 11.7 and 20.5 mcg/mL respectively were attained within 30 minutes and declined with an elimination half-life of approximately 1 hour.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ef1a6dc6-bc3d-4f09-8f92-7ff328f56561 (opens source in a new tab)
Cefotaxime label
Version not recorded · Effective date not recorded
CLINICAL PHARMACOLOGY Following IM administration of a single 500 mg or 1 g dose of cefotaxime to normal volunteers, mean peak serum concentrations of 11.7 and 20.5 mcg/mL respectively were attained within 30 minutes and declined with an elimination half-life of approximately 1 hour.
Projected row 272
- Medicine slug
- cefotetan
- Compared field
- halfLife
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 3
- Source count
- 3
- Agreement rate
- 1
- Recorded readings
3 to 4.6 hours
- Numeric value
- 3
- Unit
- hours
- Source records
- 3
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 3 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:33b13b93-58ce-44c7-b9a2-af3b3a333f80 (opens source in a new tab)
Cefotetan label
Version not recorded · Effective date not recorded
in 10 min 1 h 3 h 5 h 9 h 12 h IV 237 223 135 74 48 22 12 b IM — 20 75 91 69 33 19 a Injected over 3 minutes b Concentrations estimated from regression line The plasma elimination half-life of cefotetan is 3 to 4.6 hours after either intravenous or intramuscular administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bd22c66b-8a1c-44c8-b5b6-3ab0ce5c800e (opens source in a new tab)
Cefotetan label
Version not recorded · Effective date not recorded
maxillary sinus mucosa myometrium tonsil endometrium bile cervix peritoneal fluid ovary umbilical cord serum kidney amniotic fluid Metabolism and Excretion The plasma elimination half-life of cefotetan is 3 to 4.6 hours after either intravenous or intramuscular administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f1510f5e-d001-44e0-accb-27cf79fd4f9a (opens source in a new tab)
Cefotetan label
Version not recorded · Effective date not recorded
maxillary sinus mucosa myometrium tonsil endometrium bile cervix peritoneal fluid ovary umbilical cord serum kidney amniotic fluid Metabolism and Excretion The plasma elimination half-life of cefotetan is 3 to 4.6 hours after either intravenous or intramuscular administration.
Projected row 273
- Medicine slug
- cefpodoxime-proxetil
- Compared field
- halfLife
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 15
- Source count
- 15
- Agreement rate
- 1
- Recorded readings
3.5 hours
- Numeric value
- 3.5
- Unit
- hours
- Source records
- 15
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 15 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9d6d7f50-9838-47e3-8214-53e2dbeeadea (opens source in a new tab)
Cefpodoxime Proxetil label
Version not recorded · Effective date not recorded
(See PRECAUTIONS and DOSAGE AND ADMINISTRATION .) In subjects with mild impairment of renal function (50 to 80 mL/min creatinine clearance), the average plasma half-life of cefpodoxime was 3.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4587a7c1-cd6c-4946-a0dd-fcfe0c8504b9 (opens source in a new tab)
Cefpodoxime Proxetil label
Version not recorded · Effective date not recorded
(See PRECAUTIONS and DOSAGE AND ADMINISTRATION .) In subjects with mild impairment of renal function (50 to 80 mL/min creatinine clearance), the average plasma half-life of cefpodoxime was 3.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c36f2137-98bb-4583-89f7-6bce9582c465 (opens source in a new tab)
Cefpodoxime Proxetil label
Version not recorded · Effective date not recorded
(See PRECAUTIONS and DOSAGE AND ADMINISTRATION . ) In subjects with mild impairment of renal function (50 to 80 mL/min creatinine clearance), the average plasma half-life of cefpodoxime was 3.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:59d848e9-de7a-669b-e063-6394a90a2b35 (opens source in a new tab)
Cefpodoxime Proxetil label
Version not recorded · Effective date not recorded
(See PRECAUTIONS and DOSAGE AND ADMINISTRATION .) In subjects with mild impairment of renal function (50 to 80 mL/min creatinine clearance), the average plasma half-life of cefpodoxime was 3.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ce5646cb-a450-4c2c-8499-6ecf71b12b0e (opens source in a new tab)
Cefpodoxime Proxetil label
Version not recorded · Effective date not recorded
(See PRECAUTIONS and DOSAGE AND ADMINISTRATION .) In subjects with mild impairment of renal function (50 to 80 mL/min creatinine clearance), the average plasma half-life of cefpodoxime was 3.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fe827f61-9336-72e7-e053-6394a90af75f (opens source in a new tab)
Cefpodoxime Proxetil label
Version not recorded · Effective date not recorded
(See PRECAUTIONS and DOSAGE AND ADMINISTRATION .) In subjects with mild impairment of renal function (50 to 80 mL/min creatinine clearance), the average plasma half-life of cefpodoxime was 3.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:63777889-d306-4fc3-88da-b24859040ef4 (opens source in a new tab)
Cefpodoxime Proxetil label
Version not recorded · Effective date not recorded
(See PRECAUTIONS and DOSAGE AND ADMINISTRATION .) In subjects with mild impairment of renal function (50 to 80 mL/min creatinine clearance), the average plasma half-life of cefpodoxime was 3.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1b405104-650b-c8e3-e063-6294a90a9e8a (opens source in a new tab)
Cefpodoxime Proxetil label
Version not recorded · Effective date not recorded
(See PRECAUTIONS and DOSAGE AND ADMINISTRATION .) In subjects with mild impairment of renal function (50 to 80 mL/min creatinine clearance), the average plasma half-life of cefpodoxime was 3.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5310de78-22c3-4bee-9956-854e767b6bef (opens source in a new tab)
Cefpodoxime Proxetil label
Version not recorded · Effective date not recorded
(See PRECAUTIONS and DOSAGE AND ADMINISTRATION .) In subjects with mild impairment of renal function (50 to 80 mL/min creatinine clearance), the average plasma half-life of cefpodoxime was 3.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bc9c338c-1fc7-4bc2-a357-a78e433cbe9d (opens source in a new tab)
Cefpodoxime Proxetil label
Version not recorded · Effective date not recorded
(See PRECAUTIONS and DOSAGE AND ADMINISTRATION . ) In subjects with mild impairment of renal function (50 to 80 mL/min creatinine clearance), the average plasma half-life of cefpodoxime was 3.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:edf589b2-f796-4522-a5e6-2bd0a833922f (opens source in a new tab)
Cefpodoxime Proxetil label
Version not recorded · Effective date not recorded
(See PRECAUTIONS and DOSAGE AND ADMINISTRATION .) In subjects with mild impairment of renal function (50 to 80 mL/min creatinine clearance), the average plasma half-life of cefpodoxime was 3.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fb313728-09f1-aff8-e053-6394a90a30a8 (opens source in a new tab)
Cefpodoxime Proxetil label
Version not recorded · Effective date not recorded
(See PRECAUTIONS and DOSAGE AND ADMINISTRATION .) In subjects with mild impairment of renal function (50 to 80 mL/min creatinine clearance), the average plasma half-life of cefpodoxime was 3.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dae9cbf2-65b5-49fa-898b-924c39b86c57 (opens source in a new tab)
Cefpodoxime Proxetil label
Version not recorded · Effective date not recorded
(See PRECAUTIONS and DOSAGE AND ADMINISTRATION .) In subjects with mild impairment of renal function (50 to 80 mL/min creatinine clearance), the average plasma half-life of cefpodoxime was 3.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8519a9d8-7106-4545-bc58-859ee9a6708e (opens source in a new tab)
Cefpodoxime Proxetil label
Version not recorded · Effective date not recorded
In subjects with mild impairment of renal function (50 to 80 mL/min creatinine clearance), the average plasma half-life of cefpodoxime was 3.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5d5ca5b6-282b-4683-908c-854782255739 (opens source in a new tab)
Cefpodoxime Proxetil label
Version not recorded · Effective date not recorded
(See PRECAUTIONS and DOSAGE AND ADMINISTRATION .) In subjects with mild impairment of renal function (50 to 80 mL/min creatinine clearance), the average plasma half-life of cefpodoxime was 3.5 hours.
Projected row 274
- Medicine slug
- cefpodoxime-proxetil
- Compared field
- proteinBinding
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 15
- Source count
- 15
- Agreement rate
- 1
- Recorded readings
22 to 33%
- Numeric value
- 22
- Unit
- %
- Source records
- 15
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 15 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9d6d7f50-9838-47e3-8214-53e2dbeeadea (opens source in a new tab)
Cefpodoxime Proxetil label
Version not recorded · Effective date not recorded
odoxime Equivalents ) 1hr 2hr 3hr 4hr 6hr 8hr 12hr 100 mg 0.98 1.4 1.3 1 0.59 0.29 0.08 200 mg 1.5 2.2 2.2 1.8 1.2 0.62 0.18 400 mg 2.2 3.7 3.8 3.3 2.3 1.3 0.38 Distribution Protein binding of cefpodoxime ranges from 22 to 33% in serum and from 21 to 29% in plasma.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4587a7c1-cd6c-4946-a0dd-fcfe0c8504b9 (opens source in a new tab)
Cefpodoxime Proxetil label
Version not recorded · Effective date not recorded
ATION Dose (cefpodoxime equivalents) Time after oral ingestion 1 Dose did not exceed 200 mg. 1hr 2hr 3hr 4hr 6hr 8hr 12hr 5 mg/kg 1 1.4 2.1 2.1 1.7 0.9 0.4 0.09 Distribution Protein binding of cefpodoxime ranges from 22 to 33% in serum and from 21 to 29% in plasma.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c36f2137-98bb-4583-89f7-6bce9582c465 (opens source in a new tab)
Cefpodoxime Proxetil label
Version not recorded · Effective date not recorded
ATION Dose (cefpodoxime equivalents) Time after oral ingestion 1 Dose did not exceed 200 mg. 1hr 2hr 3hr 4hr 6hr 8hr 12hr 5 mg/kg 1 1.4 2.1 2.1 1.7 0.9 0.4 0.09 Distribution Protein binding of cefpodoxime ranges from 22 to 33% in serum and from 21 to 29% in plasma.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:59d848e9-de7a-669b-e063-6394a90a2b35 (opens source in a new tab)
Cefpodoxime Proxetil label
Version not recorded · Effective date not recorded
ATION Dose (cefpodoxime equivalents) Time after oral ingestion 1 Dose did not exceed 200 mg. 1hr 2hr 3hr 4hr 6hr 8hr 12hr 5 mg/kg 1 1.4 2.1 2.1 1.7 0.9 0.4 0.09 Distribution Protein binding of cefpodoxime ranges from 22 to 33% in serum and from 21 to 29% in plasma.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ce5646cb-a450-4c2c-8499-6ecf71b12b0e (opens source in a new tab)
Cefpodoxime Proxetil label
Version not recorded · Effective date not recorded
odoxime Equivalents ) 1hr 2hr 3hr 4hr 6hr 8hr 12hr 100 mg 0.98 1.4 1.3 1 0.59 0.29 0.08 200 mg 1.5 2.2 2.2 1.8 1.2 0.62 0.18 400 mg 2.2 3.7 3.8 3.3 2.3 1.3 0.38 Distribution Protein binding of cefpodoxime ranges from 22 to 33% in serum and from 21 to 29% in plasma.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fe827f61-9336-72e7-e053-6394a90af75f (opens source in a new tab)
Cefpodoxime Proxetil label
Version not recorded · Effective date not recorded
odoxime Equivalents ) 1hr 2hr 3hr 4hr 6hr 8hr 12hr 100 mg 0.98 1.4 1.3 1 0.59 0.29 0.08 200 mg 1.5 2.2 2.2 1.8 1.2 0.62 0.18 400 mg 2.2 3.7 3.8 3.3 2.3 1.3 0.38 Distribution Protein binding of cefpodoxime ranges from 22 to 33% in serum and from 21 to 29% in plasma.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:63777889-d306-4fc3-88da-b24859040ef4 (opens source in a new tab)
Cefpodoxime Proxetil label
Version not recorded · Effective date not recorded
TION Dose (cefpodoxime equivalents) Time after oral ingestion 1hr 2hr 3hr 4hr 6hr 8hr 12hr 1 Dose did not exceed 200 mg. 5 mg/kg 1 1.4 2.1 2.1 1.7 0.9 0.4 0.09 Distribution: Protein binding of cefpodoxime ranges from 22 to 33% in serum and from 21 to 29% in plasma.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1b405104-650b-c8e3-e063-6294a90a9e8a (opens source in a new tab)
Cefpodoxime Proxetil label
Version not recorded · Effective date not recorded
odoxime Equivalents ) 1hr 2hr 3hr 4hr 6hr 8hr 12hr 100 mg 0.98 1.4 1.3 1 0.59 0.29 0.08 200 mg 1.5 2.2 2.2 1.8 1.2 0.62 0.18 400 mg 2.2 3.7 3.8 3.3 2.3 1.3 0.38 Distribution Protein binding of cefpodoxime ranges from 22 to 33% in serum and from 21 to 29% in plasma.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5310de78-22c3-4bee-9956-854e767b6bef (opens source in a new tab)
Cefpodoxime Proxetil label
Version not recorded · Effective date not recorded
TION Dose (cefpodoxime equivalents) Time after oral ingestion 1hr 2hr 3hr 4hr 6hr 8hr 12hr 1 Dose did not exceed 200 mg. 5 mg/kg 1 1.4 2.1 2.1 1.7 0.9 0.4 0.09 Distribution: Protein binding of cefpodoxime ranges from 22 to 33% in serum and from 21 to 29% in plasma.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bc9c338c-1fc7-4bc2-a357-a78e433cbe9d (opens source in a new tab)
Cefpodoxime Proxetil label
Version not recorded · Effective date not recorded
Dose (cefpodoxime equivalents) Time after oral ingestion 1hr 2hr 3hr 4hr 6hr 8hr 12hr 5 mg/kg 1 1.4 2.1 2.1 1.7 0.9 0.4 0.09 Distribution Protein binding of cefpodoxime ranges from 22 to 33% in serum and from 21 to 29% in plasma.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:edf589b2-f796-4522-a5e6-2bd0a833922f (opens source in a new tab)
Cefpodoxime Proxetil label
Version not recorded · Effective date not recorded
TION Dose (cefpodoxime equivalents) Time after oral ingestion 1hr 2hr 3hr 4hr 6hr 8hr 12hr 1 Dose did not exceed 200 mg. 5 mg/kg 1 1.4 2.1 2.1 1.7 0.9 0.4 0.09 Distribution: Protein binding of cefpodoxime ranges from 22 to 33% in serum and from 21 to 29% in plasma.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fb313728-09f1-aff8-e053-6394a90a30a8 (opens source in a new tab)
Cefpodoxime Proxetil label
Version not recorded · Effective date not recorded
odoxime Equivalents ) 1hr 2hr 3hr 4hr 6hr 8hr 12hr 100 mg 0.98 1.4 1.3 1 0.59 0.29 0.08 200 mg 1.5 2.2 2.2 1.8 1.2 0.62 0.18 400 mg 2.2 3.7 3.8 3.3 2.3 1.3 0.38 Distribution Protein binding of cefpodoxime ranges from 22 to 33% in serum and from 21 to 29% in plasma.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dae9cbf2-65b5-49fa-898b-924c39b86c57 (opens source in a new tab)
Cefpodoxime Proxetil label
Version not recorded · Effective date not recorded
odoxime Equivalents ) 1hr 2hr 3hr 4hr 6hr 8hr 12hr 100 mg 0.98 1.4 1.3 1 0.59 0.29 0.08 200 mg 1.5 2.2 2.2 1.8 1.2 0.62 0.18 400 mg 2.2 3.7 3.8 3.3 2.3 1.3 0.38 Distribution Protein binding of cefpodoxime ranges from 22 to 33% in serum and from 21 to 29% in plasma.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8519a9d8-7106-4545-bc58-859ee9a6708e (opens source in a new tab)
Cefpodoxime Proxetil label
Version not recorded · Effective date not recorded
alents) 1hour 2hour 3hour 4hour 6hour 8hour 12hour 100 mg 0.98 1.4 1.3 1 0.59 0.29 0.08 200 mg 1.5 2.2 2.2 1.8 1.2 0.62 0.18 400 mg 2.2 3.7 3.8 3.3 2.3 1.3 0.38 Distribution Protein binding of cefpodoxime ranges from 22 to 33% in serum and from 21 to 29% in plasma.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5d5ca5b6-282b-4683-908c-854782255739 (opens source in a new tab)
Cefpodoxime Proxetil label
Version not recorded · Effective date not recorded
odoxime Equivalents ) 1hr 2hr 3hr 4hr 6hr 8hr 12hr 100 mg 0.98 1.4 1.3 1 0.59 0.29 0.08 200 mg 1.5 2.2 2.2 1.8 1.2 0.62 0.18 400 mg 2.2 3.7 3.8 3.3 2.3 1.3 0.38 Distribution Protein binding of cefpodoxime ranges from 22 to 33% in serum and from 21 to 29% in plasma.
Projected row 275
- Medicine slug
- cefpodoxime-proxetil
- Compared field
- tMax
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 15
- Source count
- 12
- Agreement rate
- 1
- Recorded readings
2 to 3 hours
- Numeric value
- 2
- Unit
- hours
- Source records
- 12
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 12 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9d6d7f50-9838-47e3-8214-53e2dbeeadea (opens source in a new tab)
Cefpodoxime Proxetil label
Version not recorded · Effective date not recorded
Over the recommended dosing range, the T max was approximately 2 to 3 hours and the T 1/2 ranged from 2.09 to 2.84 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4587a7c1-cd6c-4946-a0dd-fcfe0c8504b9 (opens source in a new tab)
Cefpodoxime Proxetil label
Version not recorded · Effective date not recorded
Over the recommended dosing range, the T max was approximately 2 to 3 hours and the T 1/2 ranged from 2.09 to 2.84 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c36f2137-98bb-4583-89f7-6bce9582c465 (opens source in a new tab)
Cefpodoxime Proxetil label
Version not recorded · Effective date not recorded
Over the recommended dosing range, the T max was approximately 2 to 3 hours and the T 1/2 ranged from 2.09 to 2.84 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:59d848e9-de7a-669b-e063-6394a90a2b35 (opens source in a new tab)
Cefpodoxime Proxetil label
Version not recorded · Effective date not recorded
Over the recommended dosing range, the T max was approximately 2 to 3 hours and the T 1/2 ranged from 2.09 to 2.84 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ce5646cb-a450-4c2c-8499-6ecf71b12b0e (opens source in a new tab)
Cefpodoxime Proxetil label
Version not recorded · Effective date not recorded
Over the recommended dosing range, the T max was approximately 2 to 3 hours and the T1/2 ranged from 2.09 to 2.84 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fe827f61-9336-72e7-e053-6394a90af75f (opens source in a new tab)
Cefpodoxime Proxetil label
Version not recorded · Effective date not recorded
Over the recommended dosing range, the T max was approximately 2 to 3 hours and the T1/2 ranged from 2.09 to 2.84 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1b405104-650b-c8e3-e063-6294a90a9e8a (opens source in a new tab)
Cefpodoxime Proxetil label
Version not recorded · Effective date not recorded
Over the recommended dosing range, the T max was approximately 2 to 3 hours and the T1/2 ranged from 2.09 to 2.84 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bc9c338c-1fc7-4bc2-a357-a78e433cbe9d (opens source in a new tab)
Cefpodoxime Proxetil label
Version not recorded · Effective date not recorded
Over the recommended dosing range, the T max was approximately 2 to 3 hours and the T 1/2 ranged from 2.09 to 2.84 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fb313728-09f1-aff8-e053-6394a90a30a8 (opens source in a new tab)
Cefpodoxime Proxetil label
Version not recorded · Effective date not recorded
Over the recommended dosing range, the T max was approximately 2 to 3 hours and the T1/2 ranged from 2.09 to 2.84 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dae9cbf2-65b5-49fa-898b-924c39b86c57 (opens source in a new tab)
Cefpodoxime Proxetil label
Version not recorded · Effective date not recorded
Over the recommended dosing range, the T max was approximately 2 to 3 hours and the T1/2 ranged from 2.09 to 2.84 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8519a9d8-7106-4545-bc58-859ee9a6708e (opens source in a new tab)
Cefpodoxime Proxetil label
Version not recorded · Effective date not recorded
Over the recommended dosing range, the T max was approximately 2 to 3 hours and the T 1/2 ranged from 2.09 to 2.84 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5d5ca5b6-282b-4683-908c-854782255739 (opens source in a new tab)
Cefpodoxime Proxetil label
Version not recorded · Effective date not recorded
Over the recommended dosing range, the T max was approximately 2 to 3 hours and the T 1/2 ranged from 2.09 to 2.84 hours.
Projected row 276
- Medicine slug
- cefprozil
- Compared field
- halfLife
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 13
- Source count
- 13
- Agreement rate
- 1
- Recorded readings
1.3 hours
- Numeric value
- 1.3
- Unit
- hours
- Source records
- 13
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 13 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3391de8b-7bc9-4624-a5c4-836135b39d99 (opens source in a new tab)
Cefprozil label
Version not recorded · Effective date not recorded
The average plasma half-life in normal subjects was 1.3 hours, while the steady-state volume of distribution was estimated to be 0.23 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:af24a86f-8072-49a6-94ec-2f17fe81812b (opens source in a new tab)
Cefprozil label
Version not recorded · Effective date not recorded
The average plasma half-life in normal subjects was 1.3 hours, while the steady-state volume of distribution was estimated to be 0.23 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:14527f4a-ce99-449d-a5a5-9edd7fb28dee (opens source in a new tab)
Cefprozil label
Version not recorded · Effective date not recorded
The average plasma half-life in normal subjects was 1.3 hours, while the steady-state volume of distribution was estimated to be 0.23 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:97675251-70b8-43bc-93ea-f9ef6bb8cb68 (opens source in a new tab)
Cefprozil label
Version not recorded · Effective date not recorded
The average plasma half-life in normal subjects was 1.3 hours, while the steady-state volume of distribution was estimated to be 0.23 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6133611e-19c1-4df2-8c23-8573aaf63020 (opens source in a new tab)
Cefprozil label
Version not recorded · Effective date not recorded
The average plasma half-life in normal subjects was 1.3 hours, while the steady-state volume of distribution was estimated to be 0.23 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d7fac9cc-30e1-4762-a01b-04f1bd3b2a56 (opens source in a new tab)
Cefprozil label
Version not recorded · Effective date not recorded
The average plasma half-life in normal subjects was 1.3 hours, while the steady-state volume of distribution was estimated to be 0.23 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3ec55c0a-1456-412e-972f-352b3135c8f2 (opens source in a new tab)
Cefprozil label
Version not recorded · Effective date not recorded
The average plasma half-life in normal subjects was 1.3 hours, while the steady-state volume of distribution was estimated to be 0.23 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8e3943b5-8c30-4c81-bcfa-aeaaa1d75fb4 (opens source in a new tab)
Cefprozil label
Version not recorded · Effective date not recorded
The average plasma half-life in normal subjects was 1.3 hours, while the steady-state volume of distribution was estimated to be 0.23 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8e292a8d-9fd6-45fb-8fb5-d8cb25a4b46d (opens source in a new tab)
Cefprozil label
Version not recorded · Effective date not recorded
The average plasma half-life in normal subjects was 1.3 hours, while the steady-state volume of distribution was estimated to be 0.23 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dc3e9cae-6f4f-4045-a11e-2fbf7f94c3c0 (opens source in a new tab)
Cefprozil label
Version not recorded · Effective date not recorded
The average plasma half-life in normal subjects was 1.3 hours, while the steady-state volume of distribution was estimated to be 0.23 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b9111a81-07c4-4458-b994-a4ad504986d8 (opens source in a new tab)
Cefprozil label
Version not recorded · Effective date not recorded
The average plasma half-life in normal subjects was 1.3 hours, while the steady-state volume of distribution was estimated to be 0.23 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:800a2ec0-4798-4423-9613-d03024cf1f0e (opens source in a new tab)
Cefprozil label
Version not recorded · Effective date not recorded
The average plasma half-life in normal subjects was 1.3 hours, while the steady-state volume of distribution was estimated to be 0.23 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d5d28d57-1f3c-4c80-ad78-0f67635f5428 (opens source in a new tab)
Cefprozil label
Version not recorded · Effective date not recorded
The average plasma half-life in normal subjects was 1.3 hours, while the steady-state volume of distribution was estimated to be 0.23 L/kg.
Projected row 277
- Medicine slug
- cefprozil
- Compared field
- proteinBinding
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 13
- Source count
- 13
- Agreement rate
- 1
- Recorded readings
36%
- Numeric value
- 36
- Unit
- %
- Source records
- 13
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 13 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3391de8b-7bc9-4624-a5c4-836135b39d99 (opens source in a new tab)
Cefprozil label
Version not recorded · Effective date not recorded
Plasma protein binding is approximately 36% and is independent of concentration in the range of 2 mcg/mL to 20 mcg/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:af24a86f-8072-49a6-94ec-2f17fe81812b (opens source in a new tab)
Cefprozil label
Version not recorded · Effective date not recorded
Plasma protein binding is approximately 36% and is independent of concentration in the range of 2 mcg/mL to 20 mcg/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:14527f4a-ce99-449d-a5a5-9edd7fb28dee (opens source in a new tab)
Cefprozil label
Version not recorded · Effective date not recorded
Plasma protein binding is approximately 36% and is independent of concentration in the range of 2 mcg/mL to 20 mcg/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:97675251-70b8-43bc-93ea-f9ef6bb8cb68 (opens source in a new tab)
Cefprozil label
Version not recorded · Effective date not recorded
Plasma protein binding is approximately 36% and is independent of concentration in the range of 2 mcg/mL to 20 mcg/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6133611e-19c1-4df2-8c23-8573aaf63020 (opens source in a new tab)
Cefprozil label
Version not recorded · Effective date not recorded
Plasma protein binding is approximately 36% and is independent of concentration in the range of 2 mcg/mL to 20 mcg/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d7fac9cc-30e1-4762-a01b-04f1bd3b2a56 (opens source in a new tab)
Cefprozil label
Version not recorded · Effective date not recorded
Plasma protein binding is approximately 36% and is independent of concentration in the range of 2 mcg/mL to 20 mcg/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3ec55c0a-1456-412e-972f-352b3135c8f2 (opens source in a new tab)
Cefprozil label
Version not recorded · Effective date not recorded
Plasma protein binding is approximately 36% and is independent of concentration in the range of 2 mcg/mL to 20 mcg/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8e3943b5-8c30-4c81-bcfa-aeaaa1d75fb4 (opens source in a new tab)
Cefprozil label
Version not recorded · Effective date not recorded
Plasma protein binding is approximately 36% and is independent of concentration in the range of 2 mcg/mL to 20 mcg/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8e292a8d-9fd6-45fb-8fb5-d8cb25a4b46d (opens source in a new tab)
Cefprozil label
Version not recorded · Effective date not recorded
Plasma protein binding is approximately 36% and is independent of concentration in the range of 2 mcg/mL to 20 mcg/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dc3e9cae-6f4f-4045-a11e-2fbf7f94c3c0 (opens source in a new tab)
Cefprozil label
Version not recorded · Effective date not recorded
Plasma protein binding is approximately 36% and is independent of concentration in the range of 2 mcg/mL to 20 mcg/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b9111a81-07c4-4458-b994-a4ad504986d8 (opens source in a new tab)
Cefprozil label
Version not recorded · Effective date not recorded
Plasma protein binding is approximately 36% and is independent of concentration in the range of 2 mcg/mL to 20 mcg/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:800a2ec0-4798-4423-9613-d03024cf1f0e (opens source in a new tab)
Cefprozil label
Version not recorded · Effective date not recorded
Plasma protein binding is approximately 36% and is independent of concentration in the range of 2 mcg/mL to 20 mcg/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d5d28d57-1f3c-4c80-ad78-0f67635f5428 (opens source in a new tab)
Cefprozil label
Version not recorded · Effective date not recorded
Plasma protein binding is approximately 36% and is independent of concentration in the range of 2 mcg/mL to 20 mcg/mL.
Projected row 278
- Medicine slug
- cefprozil
- Compared field
- volumeOfDistribution
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 13
- Source count
- 13
- Agreement rate
- 1
- Recorded readings
0.23 L/kg
- Numeric value
- 0.23
- Unit
- L/kg
- Source records
- 13
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 13 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3391de8b-7bc9-4624-a5c4-836135b39d99 (opens source in a new tab)
Cefprozil label
Version not recorded · Effective date not recorded
The average plasma half-life in normal subjects was 1.3 hours, while the steady-state volume of distribution was estimated to be 0.23 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:af24a86f-8072-49a6-94ec-2f17fe81812b (opens source in a new tab)
Cefprozil label
Version not recorded · Effective date not recorded
The average plasma half-life in normal subjects was 1.3 hours, while the steady-state volume of distribution was estimated to be 0.23 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:14527f4a-ce99-449d-a5a5-9edd7fb28dee (opens source in a new tab)
Cefprozil label
Version not recorded · Effective date not recorded
The average plasma half-life in normal subjects was 1.3 hours, while the steady-state volume of distribution was estimated to be 0.23 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:97675251-70b8-43bc-93ea-f9ef6bb8cb68 (opens source in a new tab)
Cefprozil label
Version not recorded · Effective date not recorded
The average plasma half-life in normal subjects was 1.3 hours, while the steady-state volume of distribution was estimated to be 0.23 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6133611e-19c1-4df2-8c23-8573aaf63020 (opens source in a new tab)
Cefprozil label
Version not recorded · Effective date not recorded
The average plasma half-life in normal subjects was 1.3 hours, while the steady-state volume of distribution was estimated to be 0.23 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d7fac9cc-30e1-4762-a01b-04f1bd3b2a56 (opens source in a new tab)
Cefprozil label
Version not recorded · Effective date not recorded
The average plasma half-life in normal subjects was 1.3 hours, while the steady-state volume of distribution was estimated to be 0.23 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3ec55c0a-1456-412e-972f-352b3135c8f2 (opens source in a new tab)
Cefprozil label
Version not recorded · Effective date not recorded
The average plasma half-life in normal subjects was 1.3 hours, while the steady-state volume of distribution was estimated to be 0.23 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8e3943b5-8c30-4c81-bcfa-aeaaa1d75fb4 (opens source in a new tab)
Cefprozil label
Version not recorded · Effective date not recorded
The average plasma half-life in normal subjects was 1.3 hours, while the steady-state volume of distribution was estimated to be 0.23 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8e292a8d-9fd6-45fb-8fb5-d8cb25a4b46d (opens source in a new tab)
Cefprozil label
Version not recorded · Effective date not recorded
The average plasma half-life in normal subjects was 1.3 hours, while the steady-state volume of distribution was estimated to be 0.23 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dc3e9cae-6f4f-4045-a11e-2fbf7f94c3c0 (opens source in a new tab)
Cefprozil label
Version not recorded · Effective date not recorded
The average plasma half-life in normal subjects was 1.3 hours, while the steady-state volume of distribution was estimated to be 0.23 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b9111a81-07c4-4458-b994-a4ad504986d8 (opens source in a new tab)
Cefprozil label
Version not recorded · Effective date not recorded
The average plasma half-life in normal subjects was 1.3 hours, while the steady-state volume of distribution was estimated to be 0.23 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:800a2ec0-4798-4423-9613-d03024cf1f0e (opens source in a new tab)
Cefprozil label
Version not recorded · Effective date not recorded
The average plasma half-life in normal subjects was 1.3 hours, while the steady-state volume of distribution was estimated to be 0.23 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d5d28d57-1f3c-4c80-ad78-0f67635f5428 (opens source in a new tab)
Cefprozil label
Version not recorded · Effective date not recorded
The average plasma half-life in normal subjects was 1.3 hours, while the steady-state volume of distribution was estimated to be 0.23 L/kg.
Projected row 279
- Medicine slug
- ceftazidime
- Compared field
- halfLife
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 7
- Source count
- 7
- Agreement rate
- 1
- Recorded readings
1.9 hours
- Numeric value
- 1.9
- Unit
- hours
- Source records
- 7
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 7 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9b73979c-c95a-4433-0a9d-f9cea3cb557f (opens source in a new tab)
Ceftazidime label
Version not recorded · Effective date not recorded
The half-life following IV administration was approximately 1.9 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:22d6534c-4488-48a1-8d78-e2fb908259de (opens source in a new tab)
Ceftazidime label
Version not recorded · Effective date not recorded
The half-life following IV administration was approximately 1.9 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:aec64360-8452-4987-a366-a5a4f8762ab6 (opens source in a new tab)
Ceftazidime label
Version not recorded · Effective date not recorded
The half-life following IV administration was approximately 1.9 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1ab5ae3e-e303-4499-4c89-472d7cc1e46c (opens source in a new tab)
Ceftazidime label
Version not recorded · Effective date not recorded
The half-life following IV administration was approximately 1.9 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bcc81df2-20e3-4738-bfcf-301da883c1d9 (opens source in a new tab)
Ceftazidime label
Version not recorded · Effective date not recorded
The half-life following IV administration was approximately 1.9 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:112c5457-8d71-49f5-b531-9761d7d38c93 (opens source in a new tab)
Ceftazidime label
Version not recorded · Effective date not recorded
The half-life following IV administration was approximately 1.9 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:40d48c5d-650e-461b-a67b-7e65772d1b92 (opens source in a new tab)
Ceftazidime label
Version not recorded · Effective date not recorded
The half-life following IV administration was approximately 1.9 hours.
Projected row 280
- Medicine slug
- ceftriaxone
- Compared field
- halfLife
- Comparison state
- insufficient_context
- Reason codes
- STRUCTURED_CONTEXT_MISSING
- Documents examined
- 35
- Source count
- 35
- Agreement rate
- 0.771429
- Recorded readings
5.8 to 8.7 hours
- Numeric value
- 5.8
- Unit
- hours
- Source records
- 27
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 27 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4c5c2d3f-5038-41a1-a2fe-4dcd048dbac1 (opens source in a new tab)
Ceftriaxone label
Version not recorded · Effective date not recorded
Over a 0.15 to 3 gm dose range in healthy adult subjects, the values of elimination half-life ranged from 5.8 to 8.7 hours; apparent volume of distribution from 5.78 to 13.5 L; plasma clearance from 0.58 to 1.45 L/hour; and renal clearance from 0.32 to 0.73 L/hour.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:86ec0a92-a552-4a6d-9125-a54f95e43392 (opens source in a new tab)
Ceftriaxone label
Version not recorded · Effective date not recorded
Over a 0.15 to 3 g dose range in healthy adult subjects, the values of elimination half-life ranged from 5.8 to 8.7 hours; apparent volume of distribution from 5.78 to 13.5 L; plasma clearance from 0.58 to 1.45 L/hour; and renal clearance from 0.32 to 0.73 L/hour.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ddbc3bf6-5bab-4851-ae5a-ef263cd8f255 (opens source in a new tab)
Ceftriaxone label
Version not recorded · Effective date not recorded
Over a 0.15 to 3 g dose range in healthy adult subjects, the values of elimination half-life ranged from 5.8 to 8.7 hours; apparent volume of distribution from 5.78 to 13.5 L; plasma clearance from 0.58 to 1.45 L/hour; and renal clearance from 0.32 to 0.73 L/hour.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:365fc265-8e6c-432f-9fda-911f5f7fb451 (opens source in a new tab)
Ceftriaxone label
Version not recorded · Effective date not recorded
Over a 0.15 to 3 g dose range in healthy adult subjects, the values of elimination half-life ranged from 5.8 to 8.7 hours; apparent volume of distribution from 5.78 to 13.5 L; plasma clearance from 0.58 to 1.45 L/hour; and renal clearance from 0.32 to 0.73 L/hour.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:befd73ff-cb3b-4543-8a8e-bdb9b7fc1ff0 (opens source in a new tab)
Ceftriaxone label
Version not recorded · Effective date not recorded
Over a 0.15 to 3 g dose range in healthy adult subjects, the values of elimination half-life ranged from 5.8 to 8.7 hours; apparent volume of distribution from 5.78 to 13.5 L; plasma clearance from 0.58 to 1.45 L/hour; and renal clearance from 0.32 to 0.73 L/hour.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9c801096-ca61-4b29-a1e1-5f7e7813b191 (opens source in a new tab)
Ceftriaxone label
Version not recorded · Effective date not recorded
Over a 0.15 to 3 g dose range in healthy adult subjects, the values of elimination half-life ranged from 5.8 to 8.7 hours; apparent volume of distribution from 5.78 to 13.5 L; plasma clearance from 0.58 to 1.45 L/hour; and renal clearance from 0.32 to 0.73 L/hour.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9d1f630b-e759-4395-9d01-ddc90e4fea75 (opens source in a new tab)
Ceftriaxone label
Version not recorded · Effective date not recorded
Over a 0.15 to 3 g dose range in healthy adult subjects, the values of elimination half-life ranged from 5.8 to 8.7 hours; apparent volume of distribution from 5.78 to 13.5 L; plasma clearance from 0.58 to 1.45 L/hour; and renal clearance from 0.32 to 0.73 L/hour.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b642877e-0d36-4218-afe9-0a39f35b571d (opens source in a new tab)
Ceftriaxone label
Version not recorded · Effective date not recorded
Over a 0.15 to 3 g dose range in healthy adult subjects, the values of elimination half-life ranged from 5.8 to 8.7 hours; apparent volume of distribution from 5.78 to 13.5 L; plasma clearance from 0.58 to 1.45 L/hour; and renal clearance from 0.32 to 0.73 L/hour.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fcf401df-bcdc-4773-a63b-9741c0f74b3d (opens source in a new tab)
Ceftriaxone label
Version not recorded · Effective date not recorded
Over a 0.15 to 3 g dose range in healthy adult subjects, the values of elimination half-life ranged from 5.8 to 8.7 hours; apparent volume of distribution from 5.78 to 13.5 L; plasma clearance from 0.58 to 1.45 L/hour; and renal clearance from 0.32 to 0.73 L/hour.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5cd2d96f-83e5-4326-ae87-d0ede4ba493a (opens source in a new tab)
Ceftriaxone label
Version not recorded · Effective date not recorded
8 37 29 23 15 10 5 1 gram I.V. 151 111 88 67 53 43 28 18 9 2 grams I.V. 257 192 154 117 89 74 46 31 15 Over a 0.15 to 3 g dose range in healthy adult subjects, the mean elimination half-life ranged from 5.8 to 8.7 hours, plasma clearance ranged from 0.58 to 1.45 L/hour, and renal clearance ranged from 0.32 to 0.73 L/hour.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:96f3fc1e-84f4-4e9b-91ac-19a1692f227a (opens source in a new tab)
Ceftriaxone label
Version not recorded · Effective date not recorded
Over a 0.15 to 3 gm dose range in healthy adult subjects, the values of elimination half-life ranged from 5.8 to 8.7 hours; apparent volume of distribution from 5.78 to 13.5 L; plasma clearance from 0.58 to 1.45 L/hour; and renal clearance from 0.32 to 0.73 L/hour.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:de028434-46cf-44f6-8ac6-889c7c6943b3 (opens source in a new tab)
Ceftriaxone label
Version not recorded · Effective date not recorded
Over a 0.15 to 3 g dose range in healthy adult subjects, the values of elimination half-life ranged from 5.8 to 8.7 hours; apparent volume of distribution from 5.78 to 13.5 L; plasma clearance from 0.58 to 1.45 L/hour; and renal clearance from 0.32 to 0.73 L/hour.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:53df951b-2eee-44b1-bae2-df7ed85bc0ed (opens source in a new tab)
Ceftriaxone label
Version not recorded · Effective date not recorded
Over a 0.15 to 3 g dose range in healthy adult subjects, the values of elimination half-life ranged from 5.8 to 8.7 hours; apparent volume of distribution from 5.78 to 13.5 L; plasma clearance from 0.58 to 1.45 L/hour; and renal clearance from 0.32 to 0.73 L/hour.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a25ab5ea-c46d-4562-8f7e-0ccffc2ab069 (opens source in a new tab)
Ceftriaxone label
Version not recorded · Effective date not recorded
Over a 0.15 to 3 g dose range in healthy adult subjects, the values of elimination half-life ranged from 5.8 to 8.7 hours; apparent volume of distribution from 5.78 to 13.5 L; plasma clearance from 0.58 to 1.45 L/hour; and renal clearance from 0.32 to 0.73 L/hour.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1f8776bd-4f5b-427a-849a-6b8338f7997d (opens source in a new tab)
Ceftriaxone label
Version not recorded · Effective date not recorded
Over a 0.15 to 3 g dose range in healthy adult subjects, the values of elimination half-life ranged from 5.8 to 8.7 hours; apparent volume of distribution from 5.78 to 13.5 L; plasma clearance from 0.58 to 1.45 L/hour; and renal clearance from 0.32 to 0.73 L/ hour.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1aa0a4ee-1b39-4c3d-a7a3-33dded6fe28c (opens source in a new tab)
Ceftriaxone label
Version not recorded · Effective date not recorded
Over a 0.15 to 3 g dose range in healthy adult subjects, the values of elimination half-life ranged from 5.8 to 8.7 hours; apparent volume of distribution from 5.78 to 13.5 L; plasma clearance from 0.58 to 1.45 L/hour; and renal clearance from 0.32 to 0.73 L/hour.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:128bb292-d174-4769-b3e6-9f16617f31e3 (opens source in a new tab)
Ceftriaxone label
Version not recorded · Effective date not recorded
Over a 0.15 to 3 g dose range in healthy adult subjects, the values of elimination half-life ranged from 5.8 to 8.7 hours; apparent volume of distribution from 5.78 to 13.5 L; plasma clearance from 0.58 to 1.45 L/hour; and renal clearance from 0.32 to 0.73 L/hour.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:36c07ebf-b091-483e-b2c4-f0fc0c2b4186 (opens source in a new tab)
Ceftriaxone label
Version not recorded · Effective date not recorded
Over a 0.15 to 3 g dose range in healthy adult subjects, the values of elimination half-life ranged from 5.8 to 8.7 hours; apparent volume of distribution from 5.78 to 13.5 L; plasma clearance from 0.58 to 1.45 L/hour; and renal clearance from 0.32 to 0.73 L/hour.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5cf93bc5-9e4c-4734-bc02-c7d0ac071022 (opens source in a new tab)
Ceftriaxone label
Version not recorded · Effective date not recorded
Over a 0.15 to 3 g dose range in healthy adult subjects, the values of elimination half-life ranged from 5.8 to 8.7 hours; apparent volume of distribution from 5.78 to 13.5 L; plasma clearance from 0.58 to 1.45 L/hour; and renal clearance from 0.32 to 0.73 L/hour.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ff8e830a-c288-46fb-9e19-ec2017943c07 (opens source in a new tab)
Ceftriaxone label
Version not recorded · Effective date not recorded
Over a 0.15 to 3 g dose range in healthy adult subjects, the values of elimination half-life ranged from 5.8 to 8.7 hours; apparent volume of distribution from 5.78 to 13.5 L; plasma clearance from 0.58 to 1.45 L/hour; and renal clearance from 0.32 to 0.73 L/hour.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:03283208-8616-4117-9d2b-aa8046017a4f (opens source in a new tab)
Ceftriaxone label
Version not recorded · Effective date not recorded
Over a 0.15 to 3 g dose range in healthy adult subjects, the values of elimination half-life ranged from 5.8 to 8.7 hours; apparent volume of distribution from 5.78 to 13.5 L; plasma clearance from 0.58 to 1.45 L/hour; and renal clearance from 0.32 to 0.73 L/hour.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:67153914-16bc-490d-82d7-638061618467 (opens source in a new tab)
Ceftriaxone label
Version not recorded · Effective date not recorded
es. 82 59 48 37 29 23 15 10 5 1 g IV 151 111 88 67 53 43 28 18 9 2 g IV 257 192 154 117 89 74 46 31 15 Over a 0.15 to 3 g dose range in healthy adult subjects, the mean elimination half-life ranged from 5.8 to 8.7 hours, plasma clearance ranged from 0.58 to 1.45 L/hour, and renal clearance ranged from 0.32 to 0.73 L/hour.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ac03a72c-0e35-40f9-b7fc-081badb5f19c (opens source in a new tab)
Ceftriaxone label
Version not recorded · Effective date not recorded
Over a 0.15 to 3 g dose range in healthy adult subjects, the values of elimination half-life ranged from 5.8 to 8.7 hours; apparent volume of distribution from 5.78 to 13.5 L; plasma clearance from 0.58 to 1.45 L/hour; and renal clearance from 0.32 to 0.73 L/hour.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7ea1db43-40fa-417b-8911-ae98092070a0 (opens source in a new tab)
Ceftriaxone label
Version not recorded · Effective date not recorded
Over a 0.15 to 3 g dose range in healthy adult subjects, the values of elimination half-life ranged from 5.8 to 8.7 hours; apparent volume of distribution from 5.78 to 13.5 L; plasma clearance from 0.58 to 1.45 L/hour; and renal clearance from 0.32 to 0.73 L/hour.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8351aa37-552d-471d-b293-c564dcb6ec29 (opens source in a new tab)
Ceftriaxone label
Version not recorded · Effective date not recorded
Over a 0.15 to 3 gm dose range in healthy adult subjects, the values of elimination half-life ranged from 5.8 to 8.7 hours; apparent volume of distribution from 5.78 to 13.5 L; plasma clearance from 0.58 to 1.45 L/hour; and renal clearance from 0.32 to 0.73 L/hour.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7bed9b33-29e3-4f04-9766-43a21c7ad47a (opens source in a new tab)
Ceftriaxone label
Version not recorded · Effective date not recorded
Over a 0.15 to 3 g dose range in healthy adult subjects, the values of elimination half-life ranged from 5.8 to 8.7 hours; apparent volume of distribution from 5.78 to 13.5 L; plasma clearance from 0.58 to 1.45 L/hour; and renal clearance from 0.32 to 0.73 L/hour.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:19141ccd-e66c-49a2-a794-0616028495a7 (opens source in a new tab)
Ceftriaxone label
Version not recorded · Effective date not recorded
Over a 0.15 to 3 g dose range in healthy adult subjects, the values of elimination half-life ranged from 5.8 to 8.7 hours; apparent volume of distribution from 5.78 to 13.5 L; plasma clearance from 0.58 to 1.45 L/hour; and renal clearance from 0.32 to 0.73 L/hour.
25 hours
- Numeric value
- 25
- Unit
- hours
- Source records
- 8
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 8 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5116231f-82d1-44be-b08e-560c9a50e5c5 (opens source in a new tab)
Ceftriaxone label
Version not recorded · Effective date not recorded
Based on middle ear fluid ceftriaxone concentrations in the 23 to 25 hour and the 46 to 50 hour sampling time intervals, a half-life of 25 hours was calculated.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4cdf0743-c62b-4969-b9c9-4c6400644f6c (opens source in a new tab)
Ceftriaxone label
Version not recorded · Effective date not recorded
Based on middle ear fluid ceftriaxone concentrations in the 23 to 25 hour and the 46 to 50 hour sampling time intervals, a half-life of 25 hours was calculated.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9a937e47-8c36-4656-83e1-b3c18ed9bac3 (opens source in a new tab)
Ceftriaxone label
Version not recorded · Effective date not recorded
Based on middle ear fluid ceftriaxone concentrations in the 23 to 25 hour and the 46 to 50 hour sampling time intervals, a half-life of 25 hours was calculated.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:42ba7a9d-7d2b-4eac-af59-897151a8c924 (opens source in a new tab)
Ceftriaxone label
Version not recorded · Effective date not recorded
Based on middle ear fluid ceftriaxone concentrations in the 23 to 25 hour and the 46 to 50 hour sampling time intervals, a half-life of 25 hours was calculated.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:53415af6-4072-4339-83e2-d870ae02a0e2 (opens source in a new tab)
Ceftriaxone label
Version not recorded · Effective date not recorded
Based on middle ear fluid ceftriaxone concentrations in the 23 to 25 hour and the 46 to 50 hour sampling time intervals, a half-life of 25 hours was calculated.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:85ce4f8b-77e0-48bf-9f57-93f1478befa2 (opens source in a new tab)
Ceftriaxone label
Version not recorded · Effective date not recorded
Based on middle ear fluid ceftriaxone concentrations in the 23 to 25 hour and the 46 to 50 hour sampling time intervals, a half-life of 25 hours was calculated.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:790279d4-2456-4091-abec-960b78885432 (opens source in a new tab)
Ceftriaxone label
Version not recorded · Effective date not recorded
Based on middle ear fluid ceftriaxone concentrations in the 23 to 25 hour and the 46 to 50 hour sampling time intervals, a half-life of 25 hours was calculated.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f01cf0e5-caaf-4759-ba21-50f3aceff523 (opens source in a new tab)
Ceftriaxone label
Version not recorded · Effective date not recorded
Based on middle ear fluid ceftriaxone concentrations in the 23 to 25 hour and the 46 to 50 hour sampling time intervals, a half-life of 25 hours was calculated.
Access
Query or download the projection
GET /api/datasets/source-consensus?limit=10&offset=270Allowed query parameters
- q
- Case-insensitive text search over the public fields named for this dataset.
- state
- Exact comparability state.Values: agree, differ, not_comparable, insufficient_context
- field
- Exact recorded field key.Values: bioavailability, halfLife, proteinBinding, tMax, volumeOfDistribution
- limit / offset
- Pagination is required. limit is at most 200; offset is bounded. Set format=csv for the same projected page as a download.
Reuse and corrections
Keep the boundary attached
CC BY 4.0 applies to RNAWiki licenses its selection, schema, structure, and derived projection. Quoted source passages and third-party records retain their original rights.
Cite RNAWiki, this dataset identifier, and the generated date. Keep the “does not mean” statement with any downstream display so a corpus measurement is not mistaken for medical advice.